Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-03-17
2009-08-11
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S324000
Reexamination Certificate
active
07572591
ABSTRACT:
The present invention provides an epitope recognized by an antibody (hereinafter, also referred to as an anti-ADAMTS-13 antibody) against a cleaving protease (hereinafter, also referred to as ADAMTS-13) specific to von Willebrand factor (hereinafter, also referred to as vWF), and a polypeptide comprising the epitope region. The present invention also provides a polypeptide located in a region from position 449 to position 687 in an amino acid sequence composing the ADAMTS-13, which is recognized by the anti-ADAMTS-13 antibody, or a peptide fragment derived from the polypeptide.
REFERENCES:
patent: 1 391 516 (2004-02-01), None
patent: 1 544 293 (2005-06-01), None
patent: WO 96/27387 (1996-09-01), None
Abaza MS, Atassi MZ. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin. Protein Chem. Oct. 1992;11(5):433-44.
Colman PM. Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol. 145(1):33-36, 1994.
Li CH, Yamashiro D, Tseng LF, Chang WC, Ferrar P. beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities. Proc Natl Acad Sci U S A. 77(6):3211-3214, 1980.
Soejima et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood.. Epub Jul. 17, 2003, pp. 1-36.
Zheng et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.:J Biol Chem. Aug. 8, 2003;278(32):30136-41. Epub Jun. 5, 2003.
Zheng et al. Characterization of Recombinant ADAMTS13 in COS7 cells and Identification of Domains Required for Cleavage of von Willebrand Factor. Bood, (Nov. 16, 2002) vol. 100, No. 11, Abstract No. 974.
B. Plaimauer et al., “Epitope Mapping of Anti-ADAMTS-13 Antibodies in Patients with Acquired TTP”, Blood, Nov. 16, 2003, vol. 102(II), p. 540a.
B. Plaimauer et al., “Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)” Blood, Nov. 15, 2002, vol. 100(10), pp. 3626-3632.
HE. Gerritsen et al., “Partial amino acid sequence of purified von Willebrand factor-cleaving protease”, Blood, Sep. 15, 2001, vol. 98(6), pp. 1654-1661.
CC Huang et al., “Epitope mapping of factor VIII inhibitor antibodies of Chinese origin.”, Br. J. Haematol., Jun. 2001, vol. 113(4), pp. 915-924.
MA Nardi et al., “GPIIIa- (49-66) is a major pathaophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.”, Proc. Natl. Acad. Sci. USA, Jul. 8, 1997, vol. 94(14), pp. 7589-7594.
K. Kokame et al., “Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity”, Proc. Natl. Acad. Sci. USA, Sep. 3, 2002, vol. 99(18), pp. 11902-11907.
S. Cal et al., “Cloning, expression analysis, and structural characterization of seven novel human ADAMSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.”, Gene, Jan. 23, 2002, vol. 283 (1-2), pp. 49-62.
Kenji Soejima et al., “A Noel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly the von Willebrand Factor-Cleaving Protease”, J. Biochem. 130, 475-480, 2001.
Kenji Soejima et al., “Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in Blood”, J. Biochem, 139, 147-154, 2006.
Xinglong Zheng et al., “Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura”, The Journal of Biological Chemistry, vol. 276, No. 44, Issue of Nov. 2, 2001, pp. 41059-41063.
Fujimura Yoshihiro
Matsumoto Masanori
Nakagaki Tomohiro
Soejima Kenji
Bent Stephen A.
Foley & Lardner LLP
Haddad Maher M
The Juridical Foundation Chemo-Sero-Therapeutic Research Institu
LandOfFree
Construct comprising recognition domain of antibody against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Construct comprising recognition domain of antibody against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Construct comprising recognition domain of antibody against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058918